title: Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma†.
abstract: OBJECTIVE
  Management of recurrent head and neck squamous cell carcinoma is a common and challenging clinical problem in head and neck oncology.
  
  
  OBJECTIVE
  Here we present the first reported case of super-selective intra-arterial (SSIA) microcatheter based local delivery of cetuximab for head and neck cancer. This technical report describes the techniques used to deliver the SSIA dose of cetuximab, as well as the patient outcome.
  
  
  METHODS
  This technical report is part of an ongoing Phase I Clinical Trial.
  
  
  METHODS
  The New York Head and Neck Institute (NYHNI) is a full-service otolaryngology and neurosurgery department at Lenox Hill Hospital, part of the Northwell Health System. The NYHNI serves a diverse patient population with a wide range of head and neck diseases in a tertiary hospital setting.
  
  
  METHODS
  SSIA Cetuximab.
  
  
  METHODS
  A patient presents to our clinic with recurrent unresectable squamous cell carcinoma of the nasopharynx. He is recruited into the first cohort of a phase I clinical trial to assess the safety of SSIA cetuximab, dose starting at 100mg/m2. Adjuvant chemo-radiation therapy is also given.
  
  
  METHODS
  Safety, as measured by toxicity of SSIA cetuximab.
  
  
  RESULTS
  SSIA Cetuximab has been demonstrated to be a safe and feasible procedure in this technical report.
  
  
  CONCLUSIONS
  This case illustrates technical feasibility and a very preliminary assessment of the safety of a novel delivery of a biologic agent for squamous cell carcinoma of the head and neck, which is part of an ongoing phase I clinical trial.
  
  
  BACKGROUND
  NCT02438995.
authors.affiliation: New York Head and Neck Institute, Department of Otolaryngology - Head & Neck Surgery, New York, NY, USA.
authors.forename: Tristan
authors.initials: T
authors.lastname: Tham
authors.affiliation: Hofstra - Northwell School of Medicine, Manhasset, NY, USA.
authors.forename: Timothy G
authors.initials: TG
authors.lastname: White
authors.affiliation: New York Head and Neck Institute, Department of Neurosurgery, New York, NY, USA.
authors.forename: Shamik
authors.initials: S
authors.lastname: Chakraborty
authors.affiliation: New York Head and Neck Institute, Department of Neurosurgery, New York, NY, USA.
authors.forename: Rohan R
authors.initials: RR
authors.lastname: Lall
authors.affiliation: New York Head and Neck Institute, Department of Neurosurgery, New York, NY, USA.|Department of Radiology, Lenox Hill Hospital, New York, NY, USA.
authors.forename: Rafael
authors.initials: R
authors.lastname: Ortiz
authors.affiliation: New York Head and Neck Institute, Department of Neurosurgery, New York, NY, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Langer
authors.affiliation: Department of Radiology, Lenox Hill Hospital, New York, NY, USA.
authors.forename: Deborah
authors.initials: D
authors.lastname: Shatzkes
authors.affiliation: Department of Radiology, North-Shore University Hospital, New York, NY, USA.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Filippi
authors.affiliation: New York Head and Neck Institute, Department of Otolaryngology - Head & Neck Surgery, New York, NY, USA.
authors.forename: Dennis
authors.initials: D
authors.lastname: Kraus
authors.affiliation: New York Head and Neck Institute, Department of Neurosurgery, New York, NY, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Boockvar
authors.affiliation: New York Head and Neck Institute, Department of Otolaryngology - Head & Neck Surgery, New York, NY, USA.
authors.forename: Peter D
authors.initials: PD
authors.lastname: Costantino
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab / Q000008:administration & dosage*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D000068818:Cetuximab
keywords: Intra-arterial; Phase I clinical trial; cetuximab; head and neck cancer; nasopharyngeal cancer; recurrent squamous cell carcinoma; squamous cell carcinoma